Athersys Inc (ATHX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Athersys Inc (ATHX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3050)・商品コード:DATA904C3050
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:51
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥28,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥57,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥86,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Athersys Inc (Athersys) is a biotechnology company that discovers and develops of novel and proprietary best-in-class therapies in the field of regenerative medicine. Its lead platform, MultiStem, is a patented stem cell product, developed for treating multiple disease indications such as cardiovascular diseases, inflammatory and immune disorders, neurological conditions and others. Its MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, bone marrow/hematopoietic stem cell transplantation, ischemic stroke and autoimmune disease. Its other program, 5HT2c agonist is used for treating obesity and other conditions such as schizophrenia. Athersys is headquartered in Cleveland, Ohio, the US.

Athersys Inc (ATHX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Athersys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10
Athersys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Athersys Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Athersys Enters into Partnership with MedCision 12
Athersys Enters into Co-Development Agreement for MultiStem 13
Cell Therapy Catapult Enters into Agreement with Athersys 14
Licensing Agreements 15
Athersys Expands Licensing Agreement with Healios 15
Equity Offering 17
Athersys Plans to Raise up to USD43.9 Million in Public Offering of Shares 17
Athersys Raises USD1.9 Million in Private Placement of Shares, upon Exercise of Warrants 18
Athersys Raises USD23 Million in Public Offering of Shares 19
Athersys Files Registration Statement For Public Offering Of Shares 20
Athersys Completes Private Placement Of Common Stock And Warrants For US$20.5 Million 21
Athersys Completes Private Placement Of Common Stock And Warrants For US$20 Million 22
Athersys Raises USD18.4 Million in Private Placement Of Shares 23
Athersys Completes Public Offering Of Common Stock For US$23 Million 24
Athersys Completes Private Placement Of Shares For US$9 Million 25
Athersys Inc – Key Competitors 26
Athersys Inc – Key Employees 27
Athersys Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 07, 2018: Athersys reports second quarter 2018 results 29
May 10, 2018: Athersys Reports First Quarter 2018 Results 31
Mar 13, 2018: Athersys Reports Financial Results for Fourth Quarter, Full Year 2017 33
Nov 08, 2017: Athersys Reports Third Quarter 2017 Results 35
Aug 09, 2017: Athersys Reports Second Quarter 2017 Results 37
May 09, 2017: Athersys Reports First Quarter 2017 Results 38
Mar 09, 2017: Athersys Reports Financial Results for Fourth Quarter, Full Year 2016 39
Product News 41
02/23/2017: Overview of MultiStem Clinical Trial in Japan Presentation at International Stroke Conference 2017 41
Clinical Trials 42
Nov 15, 2017: HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem Treatment for Ischemic Stroke 42
Oct 25, 2017: The Status of a Clinical Trial of Adult Stem Cell Regenerative Medicine HLCM051 in Patients with Ischemic Stroke in Japan (TREASURE study) 44
Oct 05, 2017: Athersys to Present at 2017 Cell & Gene Meeting on the Mesa and Announces Regenerative Medicine Advanced Therapy Designation From FDA 45
Sep 01, 2017: The Status of a Clinical Trial of Adult Stem Cell Regenerative Medicine HLCM051 in Patients with Ischemic Stroke in Japan (TREASURE study) 46
Aug 07, 2017: Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke 47
Mar 23, 2017: The Results from Athersys Phase 2 Trial of MultiStem Cell Therapy for Treating Ischemic Stroke Patients in the United States and Europe Published in Lancet Neurology 48
Mar 20, 2017: Two New Publications Highlight the Potential for MultiStem Treatment of Ischemic Stroke 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Athersys Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Athersys Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Athersys Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10
Athersys Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Athersys Enters into Partnership with MedCision 12
Athersys Enters into Co-Development Agreement for MultiStem 13
Cell Therapy Catapult Enters into Agreement with Athersys 14
Athersys Expands Licensing Agreement with Healios 15
Athersys Plans to Raise up to USD43.9 Million in Public Offering of Shares 17
Athersys Raises USD1.9 Million in Private Placement of Shares, upon Exercise of Warrants 18
Athersys Raises USD23 Million in Public Offering of Shares 19
Athersys Files Registration Statement For Public Offering Of Shares 20
Athersys Completes Private Placement Of Common Stock And Warrants For US$20.5 Million 21
Athersys Completes Private Placement Of Common Stock And Warrants For US$20 Million 22
Athersys Raises USD18.4 Million in Private Placement Of Shares 23
Athersys Completes Public Offering Of Common Stock For US$23 Million 24
Athersys Completes Private Placement Of Shares For US$9 Million 25
Athersys Inc, Key Competitors 26
Athersys Inc, Key Employees 27
Athersys Inc, Subsidiaries 28

List of Figures
Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Athersys Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Athersys Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Athersys Inc (ATHX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3050)販売に関する免責事項を必ずご確認ください。
★調査レポート[Athersys Inc (ATHX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆